NextPlat (NXPL) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Document Information [Line Items]
Entity Central Index Key	0001058307
Entity Registrant Name	NextPlat Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-40447
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	65-0783722
Entity Address, Address Line One	3250 Mary St., Suite 410
Entity Address, City or Town	Coconut Grove
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33133
City Area Code	305
Local Phone Number	560-5355
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,773,146
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	NXPLW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	NXPL
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash	$ 23,526,000	$ 26,307,000
Accounts receivable, net	12,928,000	8,923,000
Receivables - other, net	2,068,000	1,846,000
Inventory, net	5,610,000	5,135,000
Unbilled revenue	185,000	189,000
VAT receivable	357,000	342,000
Prepaid expenses	404,000	640,000
Notes receivable due from related party	260,000	256,000
Total Current Assets	45,338,000	43,638,000
Property and equipment, net	3,846,000	3,989,000
Goodwill	731,000	731,000
Intangible assets, net	13,725,000	14,423,000
Operating right of use assets, net	1,303,000	1,566,000
Finance right-of-use assets, net	18,000	22,000
Deposits	39,000	39,000
Prepaid expenses, net of current portion	61,000	61,000
Total Other Assets	15,877,000	16,842,000
Total Assets	65,061,000	64,469,000
Current Liabilities
Accounts payable and accrued expenses	14,893,000	13,176,000
Contract liabilities	140,000	42,000
Notes payable	233,000	312,000
Due to related party	42,000	18,000
Operating lease liabilities	532,000	532,000
Finance lease liabilities	20,000	18,000
Income taxes payable	90,000	139,000
Total Current Liabilities	15,950,000	14,237,000
Long Term Liabilities:
Long-term portion of notes payable	1,165,000	1,211,000
Operating lease liabilities, net of current portion	853,000	929,000
Finance lease liabilities, net of current portion	0	5,000
Total Liabilities	17,968,000	16,382,000
Commitments and Contingencies
Equity
Preferred stock ($0.0001 par value; 3,333,333 shares authorized)	0	0
Common stock ($0.0001 par value; 50,000,000 shares authorized, 18,724,596 and 18,724,596 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)	2,000	2,000
Additional paid-in capital	67,717,000	67,170,000
Accumulated deficit	(36,406,000)	(34,925,000)
Accumulated other comprehensive loss	(90,000)	(63,000)
Equity attributable to NextPlat Corp stockholders	31,223,000	32,184,000
Equity attributable to non-controlling interests	15,870,000	15,903,000
Total Equity	47,093,000	48,087,000
Total Liabilities and Equity	$ 65,061,000	$ 64,469,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	3,333,333	3,333,333
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	18,724,596	18,724,596
Common stock, shares outstanding (in shares)	18,724,596	18,724,596

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 17,493	$ 2,876
Cost of revenue	12,683	2,255
Gross profit	4,810	621
Operating expenses:
Selling, general and administrative	2,005	788
Salaries, wages and payroll taxes	2,624	588
Impairment loss	132	0
Professional fees	985	321
Depreciation and amortization	906	162
Total operating expenses	6,652	1,859
Loss before other (income) expense	(1,842)	(1,238)
Other (income) expense:
Interest expense	21	5
Interest earned	(215)	(10)
Other income	0	(50)
Foreign currency exchange rate variance	26	(28)
Total other income	(168)	(83)
Loss before income taxes and equity in net loss of affiliate	(1,674)	(1,155)
Income taxes	(27)	0
Loss before equity in net loss of affiliate	(1,701)	(1,155)
Equity in net loss of affiliate	0	(32)
Net loss	(1,701)	(1,187)
Net loss attributable to non-controlling interest	220	0
Net loss attributable to NextPlat Corp	(1,481)	(1,187)
Comprehensive income (loss):
Net loss	(1,701)	(1,187)
Foreign currency loss	(27)	(23)
Comprehensive loss	(1,728)	(1,210)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (1,481)	$ (1,187)
Basic weighted average common shares outstanding (in shares)	18,725	14,415
Weighted average loss per common share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)
Product [Member]
Revenue	$ 14,120	$ 2,876
Cost of revenue	12,620	2,255
Service [Member]
Revenue	3,373	0
Cost of revenue	$ 63	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2022	14,402
Balance at Dec. 31, 2022	$ 1	$ 56,963	$ (31,147)	$ (41)	$ 25,776	$ 0	$ 25,776
Stock-based compensation in connection with restricted stock awards (in shares)	39
Stock-based compensation in connection with restricted stock awards	$ 0	61	0	0	61	0	61
Comprehensive loss	0	0	0	(23)	(23)	0	(23)
Net income (loss)	$ 0	0	(1,187)	0	(1,187)	0	(1,187)
Balance (in shares) at Mar. 31, 2023	14,441
Balance at Mar. 31, 2023	$ 1	57,024	(32,334)	(64)	24,627	0	24,627
Balance (in shares) at Dec. 31, 2023	18,725
Balance at Dec. 31, 2023	$ 2	67,170	(34,925)	(63)	32,184	15,903	48,087
Stock-based compensation in connection with options granted	$ 0	160	0	0	160	0	160
Stock-based compensation in connection with restricted stock awards (in shares)	0
Stock-based compensation in connection with restricted stock awards	$ 0	387	0	0	387	65	452
Capital contribution of non-controlling interests	0	0	0	0	0	122	122
Comprehensive loss	0	0	0	(27)	(27)	0	(27)
Net income (loss)	$ 0	0	(1,481)	0	(1,481)	(220)	(1,701)
Balance (in shares) at Mar. 31, 2024	18,725
Balance at Mar. 31, 2024	$ 2	$ 67,717	$ (36,406)	$ (90)	$ 31,223	$ 15,870	$ 47,093

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,701,000)	$ (1,187,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	203,000	155,000
Change in provision for doubtful accounts	2,000	0
Amortization of intangible assets	698,000	6,000
Amortization of right-of-use assets - operating leases	129,000	49,000
Amortization of right-of-use assets - finance leases	5,000	0
Equity in net loss of affiliate	0	32,000
Stock-based compensation	612,000	243,000
Impairment loss	132,000	0
Gain on sale or disposal of property and equipment	(1,000)	0
Accounts receivable	(4,230,000)	(572,000)
Inventory	(475,000)	(877,000)
Unbilled revenue	4,000	142,000
Prepaid expense	236,000	(32,000)
Notes receivable	(4,000)	0
VAT receivable	(15,000)	(76,000)
Accounts payable and accrued expenses	1,745,000	94,000
Operating lease liabilities	(74,000)	(43,000)
Income taxes payable	(49,000)	2,000
Contract liabilities	98,000	(3,000)
Net cash used in operating activities	(2,685,000)	(2,067,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(64,000)	(69,000)
Proceeds from sale or disposal of property and equipment	1,000	0
Net cash used in investing activities	(63,000)	(69,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of note payable, related party, net	23,000	(2,000)
Capital contribution	122,000	0
Payments on finance lease liabilities	(5,000)	0
Repayments of notes payable	(141,000)	(11,000)
Net cash used in financing activities	(1,000)	(13,000)
Effect of exchange rate on cash	(32,000)	(23,000)
Net decrease in cash	(2,781,000)	(2,172,000)
Cash beginning of period	26,307,000	18,891,000
Cash end of period	23,526,000	16,719,000
SUPPLEMENTAL CASH FLOW INFORMATION
Interest	170,000	4,000
Income tax	$ 74,000	$ 0

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Operations.	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Nature of Operations [Text Block]	1. The term “Company” refers to NextPlat Corp and its wholly, majority owned and controlled subsidiaries, except where the context requires otherwise or where otherwise indicated. NextPlat Corp: NextPlat Corp, a Nevada corporation (the “Company”, “NextPlat”, “we”), formerly Orbsat Corp was incorporated in 1997. two 25 third Web3 Our wholly-owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. February 19, 2015, Our wholly-owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014. On June 22, 2022, not Progressive Care Inc.: Progressive Care Inc. (“Progressive Care”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no Florida Sunshine Brands, LLC: Florida Sunshine Brands, LLC (“Florida Sunshine”) is a Florida limited liability company and incorporated December 6, 2023.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Principles of Consolidation	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. The accompanying Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), consistent in all material respects with those applied in the 2023 10 not 2023 10 not Business acquisition of Progressive Care, Inc. On July 1, 2023, July 1, 2023, The exercise of the stock options, along with the entry into the voting agreement, resulted in a change in control of Progressive Care under the voting interest model in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combination, July 1, 2023. The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates In preparing the Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may not

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3. The significant accounting policies of the Company were described in Note 1 10 December 31, 2023 no three March 31, 2024. Cash The Company places its cash with high credit quality financial institutions. The Company’s account at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $1.0 million, are unsecured. The Company has a deposit placement agreement for Insured Cash Sweep Service (“ICS”). This service is a secure, and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000. Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the three March 31, 2024 three March 31, 2023 December 31, 2023 Unearned Revenue Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At March 31, 2024 December 31, 2023 Direct and Indirect Remuneration ( “ DIR ” ) Progressive Care reports DIR fees as a reduction of revenue on the accompanying Consolidated Statements of Operations. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three January – April 20xx July – August 20xx December 31, 2023, not second 2024. may January 1, 2024, Recent Accounting Pronouncements Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Other accounting standards that have been issued or proposed by FASB that do not not Subsequent Events The Company has evaluated subsequent events through May [ ], 2024, 21

Note 4 - Fair Value

Note 4 - Fair Value	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2 Identifiable Intangible Assets The initial recognition of the Progressive Care's identifiable intangible assets, resulting from the acquisition on July 1, 2023 3

Note 5 - Revenue

Note 5 - Revenue	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5. e-Commerce r The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not Healthcare revenue: The Company recognizes pharmacy revenue and 340B third The Company accrues an estimate of pharmacy benefit manager (“PBM”) fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. The Company recognizes COVID- 19 The following table disaggregates net revenues by categories (in thousands): Three Months Ended March 31, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 11,324 $ - e-Commerce revenue 2,865 2,876 Sub total 14,189 2,876 Revenues from services: Pharmacy 340B contract revenue 3,304 - Revenues, net $ 17,493 $ 2,876

Note 6 - Loss Per Share

Note 6 - Loss Per Share	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 6. Net income (loss) per common share is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 260: 260” not The components of basic and diluted EPS were as follows (in thousands, except per share data). Three Months Ended March 31, 2024 2023 Net loss attributable to NextPlat Corp common shareholders $ (1,481 ) $ (1,187 ) Basic weighted average common shares outstanding 18,725 14,415 Potentially dilutive common shares - - Diluted weighted average common shares outstanding 18,725 14,415 Weighted average loss per common share - basic and diluted $ (0.08 ) $ (0.08 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 105 100 105 100

Note 7 - Accounts Receivable

Note 7 - Accounts Receivable	3 Months Ended
	Mar. 31, 2024
Accounts Receivable [Member]
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 7. At March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 (Unaudited) (Audited) Gross accounts receivable – trade $ 13,202 $ 9,195 Less: allowance for doubtful accounts (274 ) (272 ) Accounts receivable – trade, net $ 12,928 $ 8,923 The Company increased the allowance for credit losses in the amount of approximately $2,000 and $0 for the three March 31, 2024 2023 Accounts receivable – trade, net for the Company as of January 1, 2023 March 31, 2023

Note 8 - Inventory

Note 8 - Inventory	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 8. At March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 (Unaudited) (Audited) Finished goods $ 5,670 $ 5,195 Less reserve for obsolete inventory (60 ) (60 ) Total $ 5,610 $ 5,135

Note 9 - VAT Receivable

Note 9 - VAT Receivable	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
VAT Accounts Receivable [Text Block]	Note 9. On January 1, 2021, March 31, 2024 December 31, 2023

Note 10 - Prepaid Expenses

Note 10 - Prepaid Expenses	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Prepaid Expenses [Text Block]	Note 10. Prepaid expenses current and long term amounted to approximately $404,000 and $61,000, respectively at March 31, 2024 December 31, 2023

Note 11 - Property and Equipmen

Note 11 - Property and Equipment, Net	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 11. Property and equipment, net consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) Building $ 2,116 $ 2,116 Vehicles 585 595 Office furniture and fixtures 543 527 Land 184 184 Leasehold improvements 167 124 Computer equipment 117 117 Rental equipment 63 60 Appliques 2,160 2,160 Website development 611 587 Construction in progress - 22 Property and equipment gross 6,546 6,492 Less: accumulated depreciation (2,700 ) (2,503 ) Property and equipment, net $ 3,846 $ 3,989 Depreciation expense was approximately $203,000 and $155,000 for the three March 31, 2024 2023

Note 12 - Intangible Assets, Ne

Note 12 - Intangible Assets, Net	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 12. Intangible assets, net consisted of the following (in thousands): March 31, 2024 (Unaudited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (1,219 ) $ 6,911 Trade names 4,700 (353 ) 4,347 Developed technology 2,880 (432 ) 2,448 Customer Contracts 250 (231 ) 19 Total intangible assets $ 15,960 $ (2,235 ) $ 13,725 December 31, 2023 (Audited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423 Amortization of customer contracts is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Comprehensive Income (Loss). For the three March 31, 2024 2023 Year Amount 2024 (remaining nine months) $ 2,023 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 13,725

Note 13 - Accounts Payable and

Note 13 - Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 13. Accounts payable and accrued expenses consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) Accounts payable $ 13,978 $ 12,142 Accrued wages and payroll liabilities 378 200 Accrued PBM fees 366 571 Customer deposits payable 54 76 Accrued other liabilities 117 187 Total $ 14,893 $ 13,176

Note 14 - Notes Payable

Note 14 - Notes Payable	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 14. Notes payable consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,118 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 229 255 Insurance premiums financing 26 103 Subtotal 1,398 1,523 Less: current portion of notes payable (233 ) (312 ) Long-term portion of notes payable $ 1,165 $ 1,211 (A) Mortgage Note Payable – collateralized In 2018, 400 December 14, 2028 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of March 31, 2024 (C) Notes Payable – Collateralized On July 16, 2020 ( £250,000, July 16, 2021, Base Rate July 16, 2020), July 15, 2026, first £4,166.67 13 July 16, 2020. 5 In April 2021, September 2021, March 31, 2024 December 31, 2023 In July 2022, January 2023. March 31, 2024 December 31, 2023 In September 2022, October 2022. March 31, 2024 December 31, 2023 Principal outstanding as of March 31, 2024 Year Amount 2024 (remaining nine months) $ 187 2025 215 2026 119 2027 124 2028 753 Thereafter - Total $ 1,398

Note 15 - Equity

Note 15 - Equity	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Equity [Text Block]	Note 15. Equity Preferred Stock We have authorized 3,333,333 shares of $0.0001 par value of preferred stock. No preferred stock was outstanding for any year presented. As of March 31, 2024 Common Stock We have authorized 50,000,000 shares of $0.0001 par value common stock. As of March 31, 2024 Listing on the Nasdaq Capital Market Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols “NXPL” and “NXPLW,” respectively, since January 21, 2022. January 21, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 not not may not For the three March 31, 2024 2023 three March 31, 2024 2023

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 16. On July 12, 2022, September 22, 2022, no December 31, 2022. April 2023, Progressive Care Inc September 2, 2022, November 11, 2022, September 2, 2022, March 6, 2019, 1 December 30, 2022. On February 1, 2023, May 2023 three March 31, 2023 three March 31, 2024 July 1, 2023. On May 5, 2023, one one On May 9, 2023, one On July 1, 2023, Also, on July 1, 2023, Next Borough Capital Fund, LP. July 7, 2023, July 7, 2024, March 31, 2024 December 31, 2023

Note 17 - Commitments and Conti

Note 17 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 17. Litigation On June 22, 2021, not June 2, 2021 not not June 21, 2022. not No. 1:21 22436 On July 5, 2022, June 22, 2021, A jury trial is set to occur during the trial court's two August 21, 2024. From time to time, the Company may not no

Note 18 - Leases

Note 18 - Leases	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 18. The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic 842 one Finance Lease Agreements In May 2018, March 2025 Operating Lease Agreements Right of use ("ROU") assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360 10, March 31, 2024 December 31, 2023 We monitor for events or changes in circumstances that require a reassessment of one On December 2, 2021, June 13, 2022, August 31, 2027. not For our facilities in Poole, England, we rent office and warehouse space of approximately 2,660 square feet for £30,000 October 6, 2022, October 31, 2023 twelve Progressive Care entered into a lease agreement for its Orlando pharmacy in August 2020. February 2026. February 2021, Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in September 2021. August 2026. Progressive Care also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in February 2025.

Note 19 - Reportable Segments

Note 19 - Reportable Segments	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 19. The Company has two 19 340B 340B The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two For the Three Months Ended March 31, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 11,324 $ - $ 11,324 e-Commerce revenue 2,865 - - 2,865 Pharmacy 340B contract revenue - 3,304 - 3,304 Revenues, net $ 2,865 $ 14,628 $ - $ 17,493 Expenses: Cost of revenue 2,060 10,623 - 12,683 Selling, general and administrative 1,166 899 (60 ) 2,005 Salaries, wages and payroll taxes 508 2,116 - 2,624 Impairment loss - 132 - 132 Professional fees 507 478 - 985 Depreciation and amortization 130 776 - 906 4,371 15,024 (60 ) 19,335 Loss before other (income) expense (1,506 ) (396 ) 60 (1,842 ) Other (expense) income (203 ) (25 ) (60 ) (168 ) Loss before income taxes (1,303 ) (371 ) - (1,674 ) Income taxes (27 ) - - (27 ) Net loss $ (1,330 ) $ (371 ) $ - $ (1,701 ) For the Three Months Ended March 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ - $ - $ - e-Commerce revenue 2,876 - - 2,876 Pharmacy 340B contract revenue - - - - Revenues, net $ 2,876 $ - $ - $ 2,876 Expenses: Cost of revenue 2,255 - - 2,255 Selling, general and administrative 788 - - 788 Salaries, wages and payroll taxes 588 - - 588 Professional fees 321 - - 321 Depreciation and amortization 162 - - 162 4,114 - - 4,114 Loss before other (income) expense (1,238 ) - - (1,238 ) Other (expense) income (83 ) - - (83 ) Loss before income taxes (1,155 ) - - (1,155 ) Income taxes - - - - Loss before equity method investment (1,155 ) - - (1,155 ) Equity in net loss of affiliate (32 ) - - (32 ) Net loss $ (1,187 ) $ - $ - $ (1,187 ) e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of March 31, 2024 $ 40,342 $ 41,398 $ (16,679 ) $ 65,061 Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469

Note 20 - Concentrations

Note 20 - Concentrations	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 20. e-Commerce operations concentrations: Customers: Sales to customers through Amazon accounted for 39.9% and 57.2% of the Company’s revenues during the three March 31, 2024 2023 No 10% Suppliers: The following table sets forth information as to each supplier that accounted for 10% three March 31, 2024 2023 For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Globalstar Europe $ 213 10.2 % $ - - % Garmin $ 301 14.3 % $ 594 20.9 % Iridium Satellite $ 270 27.2 % $ - - % Geographic The following table sets forth revenue as to each geographic location, for the (in thousands, unaudited): For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Europe $ 1,430 49.9 % $ 2,063 71.7 % North America 523 18.3 % 586 20.4 % South America 23 0.8 % 9 0.3 % Asia and Pacific 413 14.4 % 159 5.5 % Africa 476 16.6 % 59 2.1 % $ 2,865 100 % $ 2,876 100 % Healthcare operations concentrations: Suppliers: Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were 98% of total vendor purchases for the three March 31, 2024 Customers: Progressive Care s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not Progressive Care derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three Three Months Ended March 31, 2024 A 33 % B 21 % C 16 %

Note 21 - Subsequent Events

Note 21 - Subsequent Events	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 21. Acquisition of Outfitter Satellite On March 25, 2024, fitter Satellite, Inc. (“Outfitter”) in an all-cash transaction for an aggregate purchase price of $760,000.00, subject to certain adjustments (the “Aggregate Consideration”). The closing of the transaction occurred on April 1, 2024 At the closing, $660,000.00 of the Aggregate Consideration was paid to Mr. McKinley with the remaining $100,000.00 to be paid upon delivery of Outfitter’s audited financial statements for the 2022 2023 Outfitter provides consumers, commercial and government customers, with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar. RXMD Merger On April 12, 2024, Merger Agreement Merger Sub Merger On April 9, 2024, Company Lock-Up Agreements Parent Lock-Up Agreements Hybrid Lock-Up Agreements Lock-Up Agreements no

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	5. Rule 10b5 1 During the three March 31, 2024 no 10b5 1 10b5 1 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 5 - Revenue (Tables)

Note 5 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 11,324 $ - e-Commerce revenue 2,865 2,876 Sub total 14,189 2,876 Revenues from services: Pharmacy 340B contract revenue 3,304 - Revenues, net $ 17,493 $ 2,876

Note 6 - Loss Per Share (Tables

Note 6 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2024 2023 Net loss attributable to NextPlat Corp common shareholders $ (1,481 ) $ (1,187 ) Basic weighted average common shares outstanding 18,725 14,415 Potentially dilutive common shares - - Diluted weighted average common shares outstanding 18,725 14,415 Weighted average loss per common share - basic and diluted $ (0.08 ) $ (0.08 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 105 100 105 100

Note 7 - Accounts Receivable (T

Note 7 - Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Gross accounts receivable – trade $ 13,202 $ 9,195 Less: allowance for doubtful accounts (274 ) (272 ) Accounts receivable – trade, net $ 12,928 $ 8,923

Note 8 - Inventory (Tables)

Note 8 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Finished goods $ 5,670 $ 5,195 Less reserve for obsolete inventory (60 ) (60 ) Total $ 5,610 $ 5,135

Note 11 - Property and Equipm_2

Note 11 - Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Building $ 2,116 $ 2,116 Vehicles 585 595 Office furniture and fixtures 543 527 Land 184 184 Leasehold improvements 167 124 Computer equipment 117 117 Rental equipment 63 60 Appliques 2,160 2,160 Website development 611 587 Construction in progress - 22 Property and equipment gross 6,546 6,492 Less: accumulated depreciation (2,700 ) (2,503 ) Property and equipment, net $ 3,846 $ 3,989

Note 12 - Intangible Assets, _2

Note 12 - Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, 2024 (Unaudited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (1,219 ) $ 6,911 Trade names 4,700 (353 ) 4,347 Developed technology 2,880 (432 ) 2,448 Customer Contracts 250 (231 ) 19 Total intangible assets $ 15,960 $ (2,235 ) $ 13,725 December 31, 2023 (Audited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Amount 2024 (remaining nine months) $ 2,023 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 13,725

Note 13 - Accounts Payable an_2

Note 13 - Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Accounts payable $ 13,978 $ 12,142 Accrued wages and payroll liabilities 378 200 Accrued PBM fees 366 571 Customer deposits payable 54 76 Accrued other liabilities 117 187 Total $ 14,893 $ 13,176

Note 14 - Notes Payable (Tables

Note 14 - Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Debt [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,118 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 229 255 Insurance premiums financing 26 103 Subtotal 1,398 1,523 Less: current portion of notes payable (233 ) (312 ) Long-term portion of notes payable $ 1,165 $ 1,211
Schedule of Maturities of Long-Term Debt [Table Text Block]	Year Amount 2024 (remaining nine months) $ 187 2025 215 2026 119 2027 124 2028 753 Thereafter - Total $ 1,398

Note 19 - Reportable Segments (

Note 19 - Reportable Segments (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	For the Three Months Ended March 31, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 11,324 $ - $ 11,324 e-Commerce revenue 2,865 - - 2,865 Pharmacy 340B contract revenue - 3,304 - 3,304 Revenues, net $ 2,865 $ 14,628 $ - $ 17,493 Expenses: Cost of revenue 2,060 10,623 - 12,683 Selling, general and administrative 1,166 899 (60 ) 2,005 Salaries, wages and payroll taxes 508 2,116 - 2,624 Impairment loss - 132 - 132 Professional fees 507 478 - 985 Depreciation and amortization 130 776 - 906 4,371 15,024 (60 ) 19,335 Loss before other (income) expense (1,506 ) (396 ) 60 (1,842 ) Other (expense) income (203 ) (25 ) (60 ) (168 ) Loss before income taxes (1,303 ) (371 ) - (1,674 ) Income taxes (27 ) - - (27 ) Net loss $ (1,330 ) $ (371 ) $ - $ (1,701 ) For the Three Months Ended March 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ - $ - $ - e-Commerce revenue 2,876 - - 2,876 Pharmacy 340B contract revenue - - - - Revenues, net $ 2,876 $ - $ - $ 2,876 Expenses: Cost of revenue 2,255 - - 2,255 Selling, general and administrative 788 - - 788 Salaries, wages and payroll taxes 588 - - 588 Professional fees 321 - - 321 Depreciation and amortization 162 - - 162 4,114 - - 4,114 Loss before other (income) expense (1,238 ) - - (1,238 ) Other (expense) income (83 ) - - (83 ) Loss before income taxes (1,155 ) - - (1,155 ) Income taxes - - - - Loss before equity method investment (1,155 ) - - (1,155 ) Equity in net loss of affiliate (32 ) - - (32 ) Net loss $ (1,187 ) $ - $ - $ (1,187 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of March 31, 2024 $ 40,342 $ 41,398 $ (16,679 ) $ 65,061 Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469

Note 20 - Concentrations (Table

Note 20 - Concentrations (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Globalstar Europe $ 213 10.2 % $ - - % Garmin $ 301 14.3 % $ 594 20.9 % Iridium Satellite $ 270 27.2 % $ - - % For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Europe $ 1,430 49.9 % $ 2,063 71.7 % North America 523 18.3 % 586 20.4 % South America 23 0.8 % 9 0.3 % Asia and Pacific 413 14.4 % 159 5.5 % Africa 476 16.6 % 59 2.1 % $ 2,865 100 % $ 2,876 100 % Three Months Ended March 31, 2024 A 33 % B 21 % C 16 %

Note 1 - Organization and Nat_2

Note 1 - Organization and Nature of Operations. (Details Textual)	Mar. 31, 2024	Dec. 06, 2023
Florida Sunshine Brands, LLC [Member]
Subsidiary, Ownership Percentage, Parent		51%
Florida Sunshine Brands, LLC [Member] | Outer Brands FS, LLC [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner		49%
Progressive Care [Member] | Pharmco 901 [Member]
Subsidiary, Ownership Percentage, Parent	100%

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Principles of Consolidation (Details Textual)	Jul. 01, 2023
Progressive Care [Member]
Business Acquisition, Percentage of Voting Interests Acquired	53%

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023
Cash, FDIC Insured Amount	$ 250,000
Cash, Uninsured Amount	1,000,000
Contract with Customer, Liability	$ 140,000	$ 42,000
Closing Rate [Member]
Foreign Currency Exchange Rate, Translation	1.28	1.27	1.23
Yearly Average Rate [Member]
Foreign Currency Exchange Rate, Translation	1.27	1.24	1.22
Maximum [Member]
Cash, FDIC Insured Amount	$ 250,000

Note 4 - Fair Value (Details Te

Note 4 - Fair Value (Details Textual) $ in Millions	Jul. 01, 2023 USD ($)
Progressive Care [Member] | Fair Value, Inputs, Level 3 [Member]
Finite-Lived Intangible Assets, Fair Value Disclosure	$ 14.7

Note 5 - Revenue - Disaggregati

Note 5 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 17,493	$ 2,876
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0
Pharmacy 340B Contract [Member]
Revenue	3,304	0
E-Commerce Revenue [Member]
Revenue	17,493
E-Commerce Revenue [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324
E-Commerce Revenue [Member] | E-Commerce [Member]
Revenue	2,865
E-Commerce Revenue [Member] | Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue	14,189
E-Commerce Revenue [Member] | Pharmacy 340B Contract [Member]
Revenue	$ 3,304
Healthcare Operations [Member]
Revenue		2,876
Healthcare Operations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue		0
Healthcare Operations [Member] | E-Commerce [Member]
Revenue		2,876
Healthcare Operations [Member] | Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue		2,876
Healthcare Operations [Member] | Pharmacy 340B Contract [Member]
Revenue		$ 0

Note 6 - Loss Per Share - Earni

Note 6 - Loss Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net loss attributable to NextPlat Corp common shareholders	$ (1,481)	$ (1,187)
Basic weighted average common shares outstanding (in shares)	18,725	14,415
Potentially dilutive common shares (in shares)	0	0
Diluted weighted average common shares outstanding (in shares)	18,725	14,415
Weighted average loss per common share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)
Antidilutive securities (in shares)	105	100
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	105	100

Note 7 - Accounts Receivable (D

Note 7 - Accounts Receivable (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Jan. 01, 2023
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,000	$ 0
Accounts Receivable, after Allowance for Credit Loss	$ 12,928,000	$ 1,000,000	$ 8,923,000	$ 400,000

Note 7 - Accounts Receivable -

Note 7 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Jan. 01, 2023
Gross accounts receivable – trade	$ 13,202	$ 9,195
Less: allowance for doubtful accounts	(274)	(272)
Accounts receivable – trade, net	$ 12,928	$ 8,923	$ 1,000	$ 400

Note 8 - Inventory - Summary of

Note 8 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Finished goods	$ 5,670	$ 5,195
Less reserve for obsolete inventory	(60)	(60)
Total	$ 5,610	$ 5,135

Note 9 - VAT Receivable (Detail

Note 9 - VAT Receivable (Details Textual) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Value Added Tax Receivable, Current	$ 357,000	$ 342,000

Note 10 - Prepaid Expenses (Det

Note 10 - Prepaid Expenses (Details Textual) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Prepaid Expense, Current	$ 404,000	$ 640,000
Prepaid Expense, Noncurrent	$ 61,000	$ 61,000

Note 11 - Property and Equipm_3

Note 11 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Depreciation	$ 203,000	$ 155,000

Note 11 - Property and Equipm_4

Note 11 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property and equipment gross	$ 6,546	$ 6,492
Less: accumulated depreciation	(2,700)	(2,503)
Property and equipment, net	3,846	3,989
Building [Member]
Property and equipment gross	2,116	2,116
Vehicles [Member]
Property and equipment gross	585	595
Furniture and Fixtures [Member]
Property and equipment gross	543	527
Land [Member]
Property and equipment gross	184	184
Leasehold Improvements [Member]
Property and equipment gross	167	124
Computer Equipment [Member]
Property and equipment gross	117	117
Rental Equipment [Member]
Property and equipment gross	63	60
Appliques [Member]
Property and equipment gross	2,160	2,160
Website Development [Member]
Property and equipment gross	611	587
Construction in Progress [Member]
Property and equipment gross	$ 0	$ 22

Note 12 - Intangible Assets, _3

Note 12 - Intangible Assets, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Amortization of Intangible Assets	$ 698	$ 6

Note 12 - Goodwill and Intangib

Note 12 - Goodwill and Intangible Assets, Net - Summary of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets, Gross	$ 15,960	$ 15,960
Finite Lived Intangible Assets, Accumulated Amortization	(2,235)	(1,537)
Finite Lived Intangible Assets, Net	13,725	14,423
Pharmacy Records [Member]
Finite-Lived Intangible Assets, Gross	8,130	8,130
Finite Lived Intangible Assets, Accumulated Amortization	(1,219)	(807)
Finite Lived Intangible Assets, Net	6,911	7,323
Trade Names [Member]
Finite-Lived Intangible Assets, Gross	4,700	4,700
Finite Lived Intangible Assets, Accumulated Amortization	(353)	(224)
Finite Lived Intangible Assets, Net	4,347	4,476
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets, Gross	2,880	2,880
Finite Lived Intangible Assets, Accumulated Amortization	(432)	(281)
Finite Lived Intangible Assets, Net	2,448	2,599
Customer Contracts [Member]
Finite-Lived Intangible Assets, Gross	250	250
Finite Lived Intangible Assets, Accumulated Amortization	(231)	(225)
Finite Lived Intangible Assets, Net	$ 19	$ 25

Note 12 - Goodwill and Intang_2

Note 12 - Goodwill and Intangible Assets, Net - Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
2024 (remaining nine months)	$ 2,023
2025	2,672
2026	2,672
2027	2,672
2028	1,571
Thereafter	2,115
Total	$ 13,725	$ 14,423

Note 13 - Accounts Payable an_3

Note 13 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounts payable	$ 13,978	$ 12,142
Accrued wages and payroll liabilities	378	200
Accrued PBM fees	366	571
Customer deposits payable	54	76
Accrued other liabilities	117	187
Total	$ 14,893	$ 13,176

Note 14 - Notes Payable (Detail

Note 14 - Notes Payable (Details Textual)		1 Months Ended			12 Months Ended
	Jul. 16, 2020 GBP (£)	Sep. 30, 2022 USD ($)	Jul. 31, 2022 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2018 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 16, 2020 USD ($)	Jul. 16, 2020 GBP (£)
Long-Term Debt						$ 1,398,000
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Base Rate [Member]
Collateralized Promissory Note [Member] | Progressive Care [Member]
Debt Instrument, Face Amount					$ 1,530,000
Debt Instrument, Interest Rate, Stated Percentage					4.75%
Debt Instrument, Number of Payments					119
Debt Instrument, Periodic Payment					$ 11,901
Coronavirus Loans [Member] | HSBC UK Bank PLC [Member]
Debt Instrument, Face Amount								$ 338,343	£ 250,000
Foreign Currency Exchange Rate, Translation								1.353372	1.353372
Debt Instrument, Basis Spread on Variable Rate	4%
Debt Instrument, Interest Rate, Effective Percentage								0.10%	0.10%
Debt Instrument, Term (Year)	6 years
Debt Instrument, Periodic Payment, Principal | £	£ 4,166.67
Debt Instrument, Prepayment Limit, Percentage of Balance of Debenture								10%	10%
Note Obligation for Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount				$ 30,000
Debt Instrument, Interest Rate, Stated Percentage				6.90%
Debt Instrument, Number of Payments				46
Debt Instrument, Periodic Payment				$ 331
Long-Term Debt						5,000	$ 6,500
Note Obligation to Purchase Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount			$ 90,000
Debt Instrument, Interest Rate, Stated Percentage			8.78%
Debt Instrument, Number of Payments			60
Debt Instrument, Periodic Payment			$ 1,859
Long-Term Debt						70,000	74,000
Note Obligation for Vehicles [Member] | Progressive Care [Member]
Debt Instrument, Face Amount		$ 25,000
Debt Instrument, Interest Rate, Stated Percentage		8.29%
Debt Instrument, Number of Payments		24
Debt Instrument, Periodic Payment		$ 1,143
Long-Term Debt						$ 7,000	$ 10,000

Note 14 - Notes Payable - Sched

Note 14 - Notes Payable - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Note payable	$ 1,398	$ 1,523
Less: current portion of notes payable	(233)	(312)
Long-term portion of notes payable	1,165	1,211
Mortgage Note Payable Commercial Bank Collateralized [Member]
Note payable	1,118	1,140
Note Payable Uncollateralized [Member]
Note payable	25	25
Note Payable Collateralized [Member]
Note payable	229	255
Insurance Premium Financing [Member]
Note payable	$ 26	$ 103

Note 14 - Notes Payable - Sch_2

Note 14 - Notes Payable - Schedule of Future Maturities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
2024 (remaining nine months)	$ 187
2025	215
2026	119
2027	124
2028	753
Thereafter	0
Total	$ 1,398

Note 15 - Equity (Details Textu

Note 15 - Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Apr. 11, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 09, 2022
Preferred Stock, Shares Authorized (in shares)		3,333,333		3,333,333
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Preferred Stock, Shares Outstanding (in shares)		0
Common Stock, Shares Authorized (in shares)		50,000,000		50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Common Stock, Shares, Issued (in shares)		18,724,596		18,724,596
Share-Based Payment Arrangement, Expense		$ 600	$ 200
Share-Based Payment Arrangement, Expense, Tax Benefit		$ 0	$ 0
December 2022 Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)					3 years
December 2022 Private Placement [Member] | Dawson James [Member]
Warrants and Rights Outstanding, Term (Year)					3 years
April 2023 Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares)	3,428,571
Shares Issued, Price Per Share (in dollars per share)	$ 1.75
Proceeds from Issuance of Private Placement	$ 6,000

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual)

1 Months Ended

3 Months Ended

Jul. 07, 2023 USD ($)

Jul. 01, 2023 USD ($) shares

May 09, 2023 shares

May 01, 2023 USD ($)

Feb. 01, 2023 USD ($)

Dec. 30, 2022

Sep. 02, 2022 USD ($)

Jul. 12, 2022 USD ($)

Apr. 30, 2023 USD ($)

Mar. 31, 2024 USD ($) $ / shares

Mar. 31, 2023 USD ($)

Dec. 31, 2023 USD ($) $ / shares

May 05, 2023 USD ($) $ / shares shares

Aug. 30, 2022 USD ($) shares

Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

200

Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares)

105,000

Progressive Care [Member]

Investment Owned, Balance, Shares (in shares)

402,269

455,000

Investment Owned, Price Per Share (in dollars per share) | $ / shares

$ 2.2

Investment Owned, Cost | $

$ 1,000,000

Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

Proceeds from Warrant Exercises | $

$ 506,000

Investment Owned, Balance, Shares From Warrants Exercised (in shares)

230,000

Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable | $

$ 1,000,000

Debt Conversion Agreement [Member] | Predecessor Company [Member]

Long-Term Debt, Gross | $

$ 2,800,000

Lauren Sturges Fernandez [Member]

Annual Salary | $

$ 95,000

$ 125,000

Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold | $

$ 10,995

CEO and Board Member [Member] | Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable, Including Contributions by Related Parties | $

2,300,000

Chief Operating Officer [Member] | Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable | $

$ 400,000

NextPlat Corp [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares)

570,599

NextPlat Corp [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares)

45,653

Chief Executive Officer [Member] | Progressive Care [Member] | Inducement Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

190,000

Chief Executive Officer [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares)

228,240

Chief Executive Officer [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares)

18,261

Chief Executive Officer [Member] | Progressive Care [Member]

Investment Owned, Balance, Shares From Warrants Exercised (in shares)

211,470

Board Member [Member] | Progressive Care [Member] | Inducement Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

30,000

Board Member [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares)

228,240

Board Member [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares)

18,261

Board Member [Member] | Progressive Care [Member]

Investment Owned, Balance, Shares From Warrants Exercised (in shares)

130,571

Progressive Care [Member]

Management and Administrative Service Revenue, Per Month | $

$ 20,000

$ 25,000

Proceeds From Management and Administrative Service | $

$ 60,000

$ 50,000

Fernandez And Barreto [Member] | Progressive Care [Member]

Related Party, Ownership Percentage

53%

Related Party [Member]

Notes Receivable, Principal | $

$ 250,000

Notes Receivable, Interest Rate

7%

Financing Receivable, before Allowance for Credit Loss | $

$ 260,000

$ 256,000

Note 18 - Leases (Details Textu

Note 18 - Leases (Details Textual)			1 Months Ended		3 Months Ended
	Dec. 02, 2021 USD ($) ft²	May 31, 2018 USD ($)	Sep. 30, 2021 USD ($)	Aug. 31, 2020 USD ($)	Mar. 31, 2024 USD ($) ft²	Mar. 31, 2024 GBP (£) ft²	Mar. 31, 2023 USD ($)
Operating Lease, Impairment Loss					$ 132,000		$ 0
Office Space in Florida [Member]
Lessee, Operating Lease, Term of Contract (Month)	62 months
Area of Real Estate Property (Square Foot) | ft²	4,141
Annual Rent	$ 186,345
Annual Lease Increase, Percentage	3%
Facilities in Poole, England [Member]
Area of Real Estate Property (Square Foot) | ft²					2,660	2,660
Annual Rent					$ 37,107	£ 30,000
Foreign Currency Exchange Rate, Translation					1.24	1.24
Lessee, Operating Lease, Renewal Term (Month)					12 months	12 months
Progressive Care [Member] | Finance Obligation for Pharmacy Equipment [Member]
Finance Lease, Liability		$ 115,000
Finance Lease, Monthly Payment		$ 1,678
Lessee, Finance Lease, Term of Contract (Month)		84 months
Lessee, Finance Lease, Interest Rate		6%
Progressive Care [Member] | Orlando Pharmacy [Member]
Lessee, Operating Lease, Term of Contract (Month)				66 months
Operating Lease, Monthly Payment				$ 4,310
Progressive Care [Member] | North Miami Beach Pharmacy [Member]
Lessee, Operating Lease, Term of Contract (Month)			60 months
Operating Lease, Monthly Payment			$ 5,237

Note 19 - Reportable Segments_2

Note 19 - Reportable Segments (Details Textual)	3 Months Ended
	Mar. 31, 2024
Number of Reportable Segments	2

Note 19 - Reportable Segments -

Note 19 - Reportable Segments - Schedule of Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 17,493	$ 2,876
Cost of revenue	12,683	2,255
Selling, general and administrative	2,005	788
Salaries, wages and payroll taxes	2,624	588
Impairment loss	132	0
Professional fees	985	321
Depreciation and amortization	906	162
Expenses, Including Cost of Revenue	19,335	4,114
Loss before other (income) expense	(1,842)	(1,238)
Other (expense) income	(168)	(83)
Loss before income taxes	(1,674)	(1,155)
Income taxes	(27)	0
Net loss	(1,701)	(1,187)
Loss before equity method investment	(1,701)	(1,155)
Equity in net loss of affiliate	0	(32)
Segment Expense [Member]
Selling, general and administrative	2,005	788
Professional fees	985	321
Depreciation and amortization	906	162
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0
E-Commerce Revenue [Member]
Revenue	2,865	2,876
Pharmacy 340B Contract [Member]
Revenue	3,304	0
Consolidation, Eliminations [Member]
Revenue	0	0
Cost of revenue	0	0
Salaries, wages and payroll taxes	0	0
Impairment loss	0
Expenses, Including Cost of Revenue	(60)	0
Loss before other (income) expense	60	0
Other (expense) income	(60)	0
Loss before income taxes	0	0
Income taxes	0	0
Net loss	0	0
Loss before equity method investment		0
Equity in net loss of affiliate		0
Consolidation, Eliminations [Member] | Segment Expense [Member]
Selling, general and administrative	(60)	0
Professional fees	0	0
Depreciation and amortization	0	0
Consolidation, Eliminations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0	0
Consolidation, Eliminations [Member] | E-Commerce Revenue [Member]
Revenue	0	0
Consolidation, Eliminations [Member] | Pharmacy 340B Contract [Member]
Revenue	0	0
E-Commerce [Member] | Operating Segments [Member]
Revenue	2,865	2,876
Cost of revenue	2,060	2,255
Salaries, wages and payroll taxes	508	588
Impairment loss	0
Expenses, Including Cost of Revenue	4,371	4,114
Loss before other (income) expense	(1,506)	(1,238)
Other (expense) income	(203)	(83)
Loss before income taxes	(1,303)	(1,155)
Income taxes	(27)	0
Net loss	(1,330)	(1,187)
Loss before equity method investment		(1,155)
Equity in net loss of affiliate		(32)
E-Commerce [Member] | Operating Segments [Member] | Segment Expense [Member]
Selling, general and administrative	1,166	788
Professional fees	507	321
Depreciation and amortization	130	162
E-Commerce [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0	0
E-Commerce [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	2,865	2,876
E-Commerce [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	0	0
Healthcare Operations [Member]
Revenue		2,876
Healthcare Operations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue		0
Healthcare Operations [Member] | Pharmacy 340B Contract [Member]
Revenue		0
Healthcare Operations [Member] | Operating Segments [Member]
Revenue	14,628	0
Cost of revenue	10,623	0
Salaries, wages and payroll taxes	2,116	0
Impairment loss	132
Expenses, Including Cost of Revenue	15,024	0
Loss before other (income) expense	(396)	0
Other (expense) income	(25)	0
Loss before income taxes	(371)	0
Income taxes	0	0
Net loss	(371)	0
Loss before equity method investment		0
Equity in net loss of affiliate		0
Healthcare Operations [Member] | Operating Segments [Member] | Segment Expense [Member]
Selling, general and administrative	899	0
Professional fees	478	0
Depreciation and amortization	776	0
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0
Healthcare Operations [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	0	0
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	$ 3,304	$ 0

Note 19 - Reportable Segments_3

Note 19 - Reportable Segments - Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Total Assets	$ 65,061	$ 64,469
Operating Segments [Member] | E-Commerce [Member]
Total Assets	40,342	40,764
Operating Segments [Member] | Healthcare Operations [Member]
Total Assets	41,398	40,384
Consolidation, Eliminations [Member]
Total Assets	$ (16,679)	$ (16,679)

Note 20 - Concentrations (Detai

Note 20 - Concentrations (Details Textual)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Amazon [Member]
Concentration Risk, Percentage	39.90%	57.20%
Purchases [Member] | Supplier Concentration Risk [Member]
Number of Major Vendors	1
Purchases [Member] | Supplier Concentration Risk [Member] | One Vendor [Member]
Concentration Risk, Percentage	98%

Note 20 - Concentrations - Sche

Note 20 - Concentrations - Schedules of Concentration of Risk (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 17,493	$ 2,876
Purchases [Member] | Supplier Concentration Risk [Member] | Globalstar Europe [Member]
Purchases	$ 213	$ 0
Percentage	10.20%	0%
Purchases [Member] | Supplier Concentration Risk [Member] | Garmin [Member]
Purchases	$ 301	$ 594
Percentage	14.30%	20.90%
Purchases [Member] | Supplier Concentration Risk [Member] | Iridium Satellite [Member]
Purchases	$ 270	$ 0
Percentage	27.20%	0%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Europe [Member]
Percentage	49.90%	71.70%
Revenue	$ 1,430	$ 2,063
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | North America [Member]
Percentage	18.30%	20.40%
Revenue	$ 523	$ 586
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | South America [Member]
Percentage	0.80%	0.30%
Revenue	$ 23	$ 9
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Asia Pacific [Member]
Percentage	14.40%	5.50%
Revenue	$ 413	$ 159
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Africa [Member]
Percentage	16.60%	2.10%
Revenue	$ 476	$ 59
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | All Countries [Member]
Percentage	100%	100%
Revenue	$ 2,865	$ 2,876
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM A [Member]
Percentage	33%
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM B [Member]
Percentage	21%
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM C [Member]
Percentage	16%

Note 21 - Subsequent Events (De

Note 21 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Outfitter Satellite, Inc. [Member]	Apr. 01, 2024 USD ($)
Business Combination, Consideration Transferred	$ 760,000
Payments to Acquire Businesses, Gross	660,000
Business Combination, Contingent Consideration, Liability	$ 100,000